Can nicotine patches treat long COVID symptoms?
A hypothesis paper reports that several people with post-COVID-19 syndrome improved after nicotine patch application, some completely, in a matter of days. This is a published hypothesis with anecdotal treatment observations, not a controlled trial, and the author does not report a patient count.
This hypothesis paper from Bioelectronic Medicine proposes that the SARS-CoV-2 spike glycoprotein binds not only to ACE-2 receptors but also to nicotinic acetylcholine receptors, disrupting normal nerve signaling and causing long COVID symptoms. The author hypothesizes that nicotine’s higher affinity for these receptors could displace the virus and restore unimpaired cholinergic signal transmission.
What the paper reports:
- Rapid Symptom Relief: Improvements ranged from immediate and substantial to complete remission in a matter of days
- The Mechanism Proposed: The spike glycoprotein shows sections highly affine to nicotinic acetylcholine receptors, compromising interneuronal communication
- The Rationale For Nicotine: Nicotine shows an up to 30-fold higher affinity to these receptors than acetylcholine itself
- The Symptoms Targeted: Weakness, memory lapses, pain, dyspnea and other unspecific physical complaints
This paper from a German anesthesiologist presents a mechanistic hypothesis for long COVID and an unexpected potential treatment, though controlled studies are needed to test it.
Dr. Kumar’s Take
This is a hypothesis paper, and I want to be clear about what that means: the treatment observations are uncontrolled and the author reports no patient count, no dosing detail, and no systematic outcome measures. The receptor argument is biologically plausible, and a 30-fold affinity difference is a real pharmacological gap worth taking seriously as a starting point. But rapid improvement without a control group could reflect natural recovery or expectation. Nicotine carries cardiovascular risk and addiction potential, and I would not recommend anyone try this outside a trial.
The Acetylcholine Receptor Hypothesis
The author proposes that long COVID symptoms result from the SARS-CoV-2 spike glycoprotein binding to nicotinic acetylcholine receptors (nAChRs). The nAChR is described as the principal structure of cholinergic neuromodulation and is responsible for coordinated neuronal network interaction.
Viral Protein Interference occurs when the spike glycoprotein attaches to these receptors. Non-intrinsic viral nAChR attachment compromises integrative interneuronal communication substantially, which the author argues explains the cognitive, neuromuscular and mood impairment, as well as the vegetative symptoms, that characterize post-COVID-19 syndrome.
Binding Affinity is the core of the argument. Several investigators have demonstrated that the spike glycoprotein attaches not only to ACE-2 receptors but also shows sections highly affine to nAChRs.
Nicotine’s Higher Affinity for these receptors, up to 30-fold stronger than acetylcholine itself, is what the author believes could displace the virus and pave the way for unimpaired cholinergic signal transmission. This forms the basis for the treatment hypothesis.
Case Series Results
The paper reports treating several individuals suffering from post-COVID-19 syndrome with a nicotine patch application. The author does not report the number of patients, their ages, or a structured treatment protocol.
Reported Outcomes ranged from immediate and substantial improvement to complete remission in a matter of days.
The Presenting Problem was an inability to proceed with common everyday activities due to weakness, memory lapses, pain, dyspnea and other unspecific physical complaints.
Biological Mechanisms
The proposed mechanism involves competition between the viral spike glycoprotein, acetylcholine, and nicotine for the same receptor binding sites.
Cholinergic Neuromodulation is described as the system responsible for coordinated neuronal network interaction. When that coordination is disrupted, the author argues, the result is the cognitive, neuromuscular, mood and vegetative symptoms seen in post-COVID-19 syndrome.
Displacement, Not Suppression is the proposed therapeutic action. Nicotine is an agonist ligand, so the hypothesis is that it occupies the receptor in place of the virus and permits normal signaling rather than blocking the receptor.
Safety Considerations
The paper does not present systematic safety data, so the risks below come from what is already established about nicotine rather than from this report.
Cardiovascular Effects of nicotine include increased heart rate and blood pressure, which makes it potentially dangerous for patients with heart conditions.
Addiction Potential exists with any nicotine exposure. Transdermal delivery avoids the sharp peaks of inhaled nicotine, but it does not eliminate dependence risk.
Medical Supervision matters here because nothing in this paper establishes a safe dose, a duration, or a patient profile for whom the risk is justified.
Study Limitations
This is a hypothesis article, and its limitations are substantial enough that no conclusion about nicotine’s effectiveness for long COVID can be drawn from it.
No Control Group means treatment effects cannot be distinguished from natural recovery. Post-COVID-19 symptom duration is described in the paper as unpredictable, so spontaneous improvement is a live alternative explanation.
Placebo Effects are particularly relevant given the dramatic and rapid nature of the reported improvements.
No Reported Numbers on how many people were treated, how they were selected, or how symptoms were measured. That absence alone rules out any estimate of how often this works.
Future Research Directions
Randomized, double-blind, placebo-controlled trials are the obvious next step, and they would need to weigh any potential benefit against nicotine’s known risks.
Biomarker Studies could help identify which patients might benefit, if the receptor hypothesis holds. Measuring cholinergic receptor function might predict who responds.
Dose-Finding Studies are needed, since this paper provides no dosing framework to build on.
Mechanism Validation through laboratory work could confirm whether the spike glycoprotein actually occupies nicotinic acetylcholine receptors in human tissue and whether nicotine can displace it.
Related Studies and Research
- Nicotine and Mitochondrial Damage: Study Review
- Nicotine’s Addictive Potential: Lancet 2007
- Nicotine and Endothelial Function
- Why This Neurosurgeon Will Never Use Nicotine
FAQs
How quickly did patients improve with nicotine patches?
The author reports improvements ranging from immediate and substantial to complete remission in a matter of days.
What dose of nicotine was used?
The paper describes nicotine patch application without a dosing protocol I can report.
Could this just be a placebo effect?
That is a serious concern with this design. Without a control group, actual treatment effects cannot be separated from placebo responses or natural recovery over time.
Is nicotine therapy safe for long COVID patients?
Nicotine carries cardiovascular risks and addiction potential, and this paper does not establish safety. Any use of it as a treatment belongs in a supervised trial.
Is this an established long COVID treatment?
No. This hypothesis remains experimental and requires validation through proper clinical trials.
Bottom Line
This hypothesis paper argues that the SARS-CoV-2 spike glycoprotein disrupts nervous system function by binding to nicotinic acetylcholine receptors, and that nicotine, with up to 30-fold higher affinity than acetylcholine, might displace it and restore normal signaling. The author reports treating several individuals with nicotine patches and seeing improvements ranging from immediate and substantial to complete remission in a matter of days. That is an uncontrolled observation without a reported patient count, so it cannot establish effectiveness. The mechanism deserves a randomized trial. Given nicotine’s known cardiovascular and addiction risks, this is not something to try on your own.
